Erik Ramon-Gil

6PUBLICATIONS
64CO-AUTHORS
Haematological tumoursCancer cell biologyCancer diagnosisMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 13, 2026
Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma.

|Mar 11, 2026
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Bruno Beernaert, Rose L Jady-Clark, Parin Shah

|May 16, 2025
Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening.

Amy L Collins, Keara Kirkness, Erik Ramon-Gil

|Mar 06, 2024
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.

Rebecca Garnham, Daniel Geh, Ryan Nelson

|Aug 03, 2023
Harnessing neutrophil plasticity for HCC immunotherapy.

Erik Ramon-Gil, Daniel Geh, Jack Leslie

|Jun 22, 2021
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.

Laura Torrens, Carla Montironi, Marc Puigvehí

Pageof 1

Frequent Collaborators

5 joint publications

Jack Leslie

2 joint publications

Derek A Mann

2 joint publications

Daniel Geh

2 joint publications

Josep M Llovet